Dorothy R Barnard
Affiliation: Nova Scotia
- Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentationDorothy R Barnard
Dalhousie University, Halifax, NS
Blood 100:427-34. 2002..The findings of this study confirm that most children with tMDS/tAML have disease resistant to current therapies. Standard-timing induction appears less effective for this population...
- Development of disease-specific health-related quality-of-life instruments for children with immune thrombocytopenic purpura and their parentsDorothy Barnard
IWK Health Center, Dalhousie University, 5850 University Avenue, Halifax, Nova Scotia B3J 3G9, Canada
J Pediatr Hematol Oncol 25:56-62. 2003..ITP is usually a self-limited disorder. With current controversy over management approaches, an evaluation of the disease burden experienced by the child and the family may assist with the assessment of alternative treatment approaches...
- Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology GroupDorothy R Barnard
IWK Health Centre, Halifax, Nova Scotia, Canada
Pediatr Blood Cancer 49:17-22. 2007..Myelodysplastic syndromes (MDS), acute erythroleukemia (FAB M6), and acute megakaryocytic leukemia (FAB M7) have overlapping features...
- The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginaseLesleigh S Abbott
Department of Pediatrics, Dalhousie University and Isaak Walton Killam Health Centre, Halifax, NS, Canada
Blood 114:5146-51. 2009..Neither FFP nor CRY protected against CNST, suggesting prophylaxis is unwarranted for unselected ALL patients. However, prophylactic replacement for HR patients in induction may be cost-effective...
- Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survivalSteven Neudorf
American Family Life Assurance Company AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
Blood 103:3655-61. 2004..014) were associated with improved relapse-free survival (RFS). Our results show that children older than 10 years are at higher risk for developing severe GVHD; acute GVHD is associated with favorable RFS...
- Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891Alan S Gamis
Section of Hematology Oncology Blood and Marrow Transplantation, Children s Mercy Hospital and Clinics, 2401 Gillham Rd, Kansas City, MO 64108, USA
J Clin Oncol 21:3415-22. 2003..To determine the outcome of children with Down syndrome (DS) and acute myeloid leukemia (AML) receiving standard timing chemotherapy without bone marrow transplantation (BMT), with determination of prognostic factors...
- Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer GroupWilliam G Woods
AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
J Clin Oncol 20:434-40. 2002..We report the first large prospective study of children with myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) treated in a uniform fashion on Children's Cancer Group protocol 2891...
- Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer GroupKathryn E Dusenbery
University of Minnesota, Minneapolis, USA
J Pediatr Hematol Oncol 25:760-8. 2003..To describe features of patients with acute myeloid leukemia presenting with extramedullary leukemic tumors (EML)...
- Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961Draga Barbaric
Division of Hematology Oncology BMT, BC s Children s Hospital, Vancouver, BC, Canada
Blood 109:2314-21. 2007..There was no significant outcome difference between DS-associated AML-M0 and non-M0 children. This study suggests that intensively treated non-DS-associated AML-M0 children have an inferior outcome compared with children with non-M0 AML...
- Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology groupBeverly J Lange
University of Pennsylvania School of Medicine and The Children s Hospital of Philadelphia, Division of Oncology, Philadelphia, PA, USA
Blood 111:1044-53. 2008..No new agent improved outcomes; experience may have contributed to better results time...